|

Capivasertib Clinical Trials

14 actively recruiting trials across 9 locations

Also known as: AZD5363, TRUQAP, Truqap

Pipeline

Phase 1: 2Phase 2: 4Phase 3: 4Phase 1/2: 4

Top Sponsors

  • AstraZeneca3
  • West German Study Group1
  • VA Office of Research and Development1
  • University of Chicago1
  • Stemline Therapeutics, Inc.1

Indications

  • Cancer14
  • Breast Cancer8
  • Metastatic Breast Cancer4
  • HER2-negative Breast Cancer2
  • Advanced Breast Cancer2

Other5 trials

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
Phase 2
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Phase 3
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Phase 2
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Phase 3

Birmingham, Alabama1 trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

University of Alabama at Birmingham Cancer Center

Phase 2

Dothan, Alabama1 trial

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

Dothan Hematology and Oncology

Phase 1/2

Gilbert, Arizona1 trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 3

Tucson, Arizona1 trial

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Research Site

Phase 3

Los Angeles, California1 trial

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

START Los Angeles

Phase 1/2

Rialto, California1 trial

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Research Site

Phase 1

West Los Angeles, California1 trial

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Phase 2

Chicago, Illinois1 trial

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

University of Chicago Medicine Comprehensive Cancer Center

Phase 1/2

Houston, Texas1 trial

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.